Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Verapamil and Rifampin Effect on P-Glycoprotein Expression in Hepatocellular Carcinoma

Amir Jalali 1 , * , Sepideh Ghasemian 1 , Hossein Najafzadeh 2 , Hamid Galehdari 3 , Masoud Reza Seifi 4 , Fateme Zangene 5 and Shaiesteh Dehdardargahi 6
Authors Information
1 Toxicology Research Center, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Pharmacology, Faculty of Veterinary Medicine, Shahid Chamran University, Ahvaz, IR Iran
3 Department of Genetic, Faculty of Sciences, Shahid Chamran University, Ahvaz, IR Iran
4 Department of Virology, Faculty of Veterinary Medicine, Shahid Chamran University, Ahvaz, IR Iran
5 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
6 School of Medicine, Arvand Medical Science University, International Branch of Jundishapur University of Medical Sciences, Abadan, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 01, 2014, 9 (4); e17741
  • Published Online: October 10, 2014
  • Article Type: Research Article
  • Received: January 19, 2014
  • Revised: July 26, 2014
  • Accepted: September 6, 2014
  • DOI: 10.17795/jjnpp-17741

To Cite: Jalali A, Ghasemian S, Najafzadeh H, Galehdari H, Seifi M R, et al. Verapamil and Rifampin Effect on P-Glycoprotein Expression in Hepatocellular Carcinoma, Jundishapur J Nat Pharm Prod. 2014 ; 9(4):e17741. doi: 10.17795/jjnpp-17741.

Abstract
Copyright © 2014, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol. 2006; 207(3): 571-81[DOI][PubMed]
  • 2. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010; 119(1): 125-30[DOI][PubMed]
  • 3. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 2009; 69(16): 6396-404[DOI][PubMed]
  • 4. Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep. 2011; 38(5): 3075-82[DOI][PubMed]
  • 5. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 2009; 69(23): 8996-9002[DOI][PubMed]
  • 6. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003; 9(2): 827-36[PubMed]
  • 7. Chen F, Wang T, Wang J, Wang ZQ, Qian M. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Acta Pharmacol Sin. 2008; 29(4): 458-64[DOI][PubMed]
  • 8. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009; 69(9): 3918-26[DOI][PubMed]
  • 9. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, et al. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J Gastroenterol. 2009; 15(11): 1373-80[PubMed]
  • 10. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. 2010; 10: 79[DOI][PubMed]
  • 11. Shaarawy SM, Tohamy AA, Elgendy SM, Elmageed ZY, Bahnasy A, Mohamed MS, et al. Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. Int J Biol Sci. 2009; 5(6): 549-57[PubMed]
  • 12. Nermin AH, Sadik SA,, Maraghy EL,, Manal FL. Diethylnitrosamine-induced hepatocarcinogenesis in rats: possible chemoprevention by blueberries. Afr J Biochem Res. 2008; 2(1): 81-7
  • 13. Ikeda H, Nakano G, Nagashima K, Sakamoto K, Harasawa N, Kitamura T, et al. Verapamil enhancement of antitumor effect of cis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblastoma. Cancer Res. 1987; 47(1): 231-4[PubMed]
  • 14. Holmstock N, Gonzalez FJ, Baes M, Annaert P, Augustijns P. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein. Mol Pharm. 2013; 10(3): 1056-62[DOI][PubMed]
  • 15. Ghasemian S, Najafzadeh H, Seifi MR, Jalali A, Galehdari H. Developing high performance and cost effective real time (PCR) for P-glycoprotein gene expression analysis in rat. Afr J Biotech. 2012; : 11501-8
  • 16. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009; 36(4-5): 580-90[DOI][PubMed]
  • 17. Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlotzer-Schrehardt U, et al. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia. 2010; 12(7): 550-61[PubMed]
  • 18. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem. 1993; 268(4): 2946-52[PubMed]
  • 19. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993; 85(8): 632-9[PubMed]
  • 20. Lee CH, Bradley G, Ling V. Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability. Cell Growth Differ. 1995; 6(3): 347-54[PubMed]
  • 21. Kren BT, Trembley JH, Steer CJ. Alterations in mRNA stability during rat liver regeneration. Am J Physiol. 1996; 270(5 Pt 1)-77[PubMed]
  • 22. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Ostergaard M, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest. 2007; 67(2): 123-34[DOI][PubMed]
  • 23. Becquemont L, Camus M, Eschwege V, Barbu V, Rey E, Funck-Brentano C, et al. Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam Clin Pharmacol. 2000; 14(5): 519-25[PubMed]
  • 24. Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos. 2002; 30(1): 20-6[PubMed]
  • 25. Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther. 2009; 329(1): 141-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments